Carolina Barnett-Tapia
Biographic Data
| ID | 7695541 |
|---|---|
| NAME | Carolina Barnett-Tapia |
| GIVEN NAMES | Carolina |
| FAMILY NAME | Barnett-Tapia |
| SIGNATURE | BARNETT-TAPIA C |
| AFFILIATIONS | University Health Network |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Myasthenia gravis in Latin America and the Caribbean
Latin-American and Caribbean (LAC) countries face persistent challenges in achieving universal health coverage, with out-of-pocket healthcare expenditures posing a significant barrier. Access to care for rare diseases, such as myasthenia gravis (MG), is significantly impacted. We conducted an exploratory descriptive study between LAC countries, and we assessed the availability of diagnostic and therapeutic resources for MG across 12 LAC countries…
Effect of the Covid-19 pandemic on initiations of opioid agonist therapy in Ontario
BACKGROUND: Maintaining access to opioid agonist therapy (OAT) was a key concern at the COVID-19 pandemic onset. Consequently, Ontario introduced guidance for changes to OAT delivery, including relaxed take-home dosing and expanded virtual care. We examined how the pandemic influenced OAT initiation trends. METHODS: We conducted a population-based, retrospective interrupted time series analysis using linked administrative health data from March 2…
Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R)
To estimate the minimal clinically important difference (MCID) for the MG-QOL15R. Data from two multi-country myasthenia gravis studies were used: the ADAPT RCT (n = 157) and the MyRealWorld-MG (MRW-MG) survey (n = 92). MCIDs were estimated using four anchor-based methods: change difference (CD), receiver operating characteristic (ROC) curve with Area Under the Curve (AUC), linear regression, and equipercentile linking. MG-Activities of Daily Liv…
No prominent works on this page.
Myasthenia gravis in Latin America and the Caribbean
Latin-American and Caribbean (LAC) countries face persistent challenges in achieving universal health coverage, with out-of-pocket healthcare expenditures posing a significant barrier. Access to care for rare diseases, such as myasthenia gravis (MG), is significantly impacted. We conducted an exploratory descriptive study between LAC countries, and we assessed the availability of diagnostic and therapeutic resources for MG across 12 LAC countries…
Effect of the Covid-19 pandemic on initiations of opioid agonist therapy in Ontario
BACKGROUND: Maintaining access to opioid agonist therapy (OAT) was a key concern at the COVID-19 pandemic onset. Consequently, Ontario introduced guidance for changes to OAT delivery, including relaxed take-home dosing and expanded virtual care. We examined how the pandemic influenced OAT initiation trends. METHODS: We conducted a population-based, retrospective interrupted time series analysis using linked administrative health data from March 2…
Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R)
To estimate the minimal clinically important difference (MCID) for the MG-QOL15R. Data from two multi-country myasthenia gravis studies were used: the ADAPT RCT (n = 157) and the MyRealWorld-MG (MRW-MG) survey (n = 92). MCIDs were estimated using four anchor-based methods: change difference (CD), receiver operating characteristic (ROC) curve with Area Under the Curve (AUC), linear regression, and equipercentile linking. MG-Activities of Daily Liv…
Myasthenia gravis (2 works) · Myasthenia Gravis and Thymoma (2 works) · Parkinson's Disease and Spinal Disorders (2 works) · 2019-20 coronavirus outbreak (1 work) · Adrenal Hormones and Disorders (1 work) · Agonist (1 work) · Coagulation, Bradykinin, Polyphosphates, and Angioedema (1 work) · Confidence interval (1 work) · COVID-19 and healthcare impacts (1 work) · COVID-19 and Mental Health (1 work)